Global intra-abdominal infections market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 8.50% in the above mentioned forecast period.
Request For a Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-intra-abdominal-infections-market
Intra-abdominal infection (IAI) is the inflammation of the single organ in the entire inter-abdominal area. It includes appendicitis, food poisoning, diverticulitis, intra-abdominal abscess, infection by Helicobacter pylori and diarrhea. The common symptoms of this condition are high fever, diarrhea, abdominal pain and nausea.
Growing demand of accurate non-surgical treatment, growing geriatric population, rise in the incidence of chronic and infectious diseases, growing healthcare expenditure, increasing prevalence of diseases such as appendicitis, infection by Helicobacter pylori, diverticulitis, abscess and rising awareness towards about treatment procedures are the factors that will expand the intra-abdominal infections market.
North America dominates the intra-abdominal infections market due to the presence of major key players, well-developed healthcare sector, adequate availability of antibiotics, increasing research and development activities and high prevalence of reported cases in this region. Asia-Pacific is expected to grow during the forecast period 2021 to 2028 due to the rapidly growing pharmaceutical industries, rise in public–private partnerships for the promotion of research at academic levels, rising investment in the healthcare sector and awareness about antibiotic therapy for IAI.
The major players covered in the intra-abdominal infections market report are Novartis AG, Sanofi, Pfizer Inc., Abbott, Bayer AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Allergan, Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Lilly, Aurobindo Pharma, Lupin, Zydus Cadila, Dr. Reddy’s Laboratories Ltd., Atox Bio, Sumitomo Dainippon Pharma Co., Ltd., Tetraphase Pharmaceuticals, Inc., AstraZeneca, and Bristol-Myers Squibb Company, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]
